113 related articles for article (PubMed ID: 29088977)
21. Beneficial effects of beta-blockers and angiotensin-converting enzyme inhibitors in Duchenne muscular dystrophy.
Ogata H; Ishikawa Y; Ishikawa Y; Minami R
J Cardiol; 2009 Feb; 53(1):72-8. PubMed ID: 19167641
[TBL] [Abstract][Full Text] [Related]
22. Angiotensin receptor blockers (ARB) outperform angiotensin-converting enzyme (ACE) inhibitors on ischemic stroke prevention in patients with hypertension and diabetes - A real-world population study in Taiwan.
Pai PY; Muo CH; Sung FC; Ho HC; Lee YT
Int J Cardiol; 2016 Jul; 215():114-9. PubMed ID: 27111172
[TBL] [Abstract][Full Text] [Related]
23. Comparison of medical therapy dosing in outpatients cared for in cardiology practices with heart failure and reduced ejection fraction with and without device therapy: report from IMPROVE HF.
Heywood JT; Fonarow GC; Yancy CW; Albert NM; Curtis AB; Gheorghiade M; Inge PJ; McBride ML; Mehra MR; O'Connor CM; Reynolds D; Walsh MN
Circ Heart Fail; 2010 Sep; 3(5):596-605. PubMed ID: 20634483
[TBL] [Abstract][Full Text] [Related]
24. [Temporal trends in pharmacological therapy in the IN-CHF registry from 1995 to 2005].
Fabbri G; Gorini M; Maggioni AP; Di Lenarda A;
G Ital Cardiol (Rome); 2007 Feb; 8(2):102-6. PubMed ID: 17402354
[TBL] [Abstract][Full Text] [Related]
25. Augmented sympathoinhibitory effect of valsartan when added to angiotensin-converting enzyme inhibitor in patients with left ventricular dysfunction.
Kawamura A; Yuasa F; Yokoe H; Masue Y; Sugiura T; Iwasaka T
J Cardiol; 2009 Apr; 53(2):171-8. PubMed ID: 19304119
[TBL] [Abstract][Full Text] [Related]
26. Left Ventricular Dysfunction and Chemotherapeutic Agents.
Clasen SC; Wald JW
Curr Cardiol Rep; 2018 Mar; 20(4):20. PubMed ID: 29520629
[TBL] [Abstract][Full Text] [Related]
27. Comparative Effectiveness of Angiotensin II Receptor Blockers Versus Angiotensin-Converting Enzyme Inhibitors Following Contemporary Treatments in Patients with Acute Myocardial Infarction: Results from the Korean Working Group in Myocardial Infarction (KorMI) Registry.
Song PS; Seol SH; Seo GW; Kim DK; Kim KH; Yang JH; Hahn JY; Gwon HC; Ahn Y; Jeong MH; Song YB; Kim DI;
Am J Cardiovasc Drugs; 2015 Dec; 15(6):439-49. PubMed ID: 26153396
[TBL] [Abstract][Full Text] [Related]
28. Critical evaluation of the optimal medical therapy in the cardiac resynchronization therapy candidates--single centre experience.
Vondráková D; Málek F; Dvorák J; Sedivá L; Kupec J; Petrů J; Táborský M; Neuzil P
Vnitr Lek; 2011 Oct; 57(10):799-802. PubMed ID: 22097686
[TBL] [Abstract][Full Text] [Related]
29. Improving the management of patients after myocardial infarction, from admission to discharge.
Amin A
Clin Ther; 2006 Oct; 28(10):1509-39. PubMed ID: 17157110
[TBL] [Abstract][Full Text] [Related]
30. Mechanistic and clinical rationales for using beta-blockers in heart failure.
Bristow MR
J Card Fail; 2000 Jun; 6(2 Suppl 1):8-14. PubMed ID: 10908093
[TBL] [Abstract][Full Text] [Related]
31. The role of renin angiotensin system antagonists in the prevention of doxorubicin and trastuzumab induced cardiotoxicity.
Akolkar G; Bhullar N; Bews H; Shaikh B; Premecz S; Bordun KA; Cheung DY; Goyal V; Sharma AK; Garber P; Singal PK; Jassal DS
Cardiovasc Ultrasound; 2015 Apr; 13():18. PubMed ID: 25889218
[TBL] [Abstract][Full Text] [Related]
32. Additive beneficial effects of beta blockers in the prevention of symptomatic heart failure.
Genovesi Ebert A; Colivicchi F; Malvezzi Caracciolo M; Riccio C
Monaldi Arch Chest Dis; 2009 Mar; 72(1):18-22. PubMed ID: 19645208
[TBL] [Abstract][Full Text] [Related]
33. Effects of ACE-inhibitors and beta-blockers on left ventricular remodeling in chronic heart failure.
Khattar RS
Minerva Cardioangiol; 2003 Apr; 51(2):143-54. PubMed ID: 12783070
[TBL] [Abstract][Full Text] [Related]
34. Heart failure years after cancer treatment.
Montoro N; López-Sendón JL
Future Cardiol; 2015 Jul; 11(4):433-40. PubMed ID: 26234396
[TBL] [Abstract][Full Text] [Related]
35. Renoprotective Effect of the Combination of Renin-angiotensin System Inhibitor and Calcium Channel Blocker in Patients with Hypertension and Chronic Kidney Disease.
Huang RS; Cheng YM; Zeng XX; Kim S; Fu P
Chin Med J (Engl); 2016 Mar; 129(5):562-9. PubMed ID: 26904991
[TBL] [Abstract][Full Text] [Related]
36. Effects of beta blockers on ventricular dysfunction after myocardial infarction: tolerability and survival effects.
Held P
Am J Cardiol; 1993 Mar; 71(9):39C-44C. PubMed ID: 8096674
[TBL] [Abstract][Full Text] [Related]
37. Response of doxorubicin-induced cardiomyopathy to the current management strategy of heart failure.
Tallaj JA; Franco V; Rayburn BK; Pinderski L; Benza RL; Pamboukian S; Foley B; Bourge RC
J Heart Lung Transplant; 2005 Dec; 24(12):2196-201. PubMed ID: 16364871
[TBL] [Abstract][Full Text] [Related]
38. [Treatment of heart failure based on large-scale clinical trials: renin-angiotensin system antagonists and beta-blockers].
Kubota T; Takeshita A
Nihon Rinsho; 2003 May; 61(5):801-6. PubMed ID: 12755006
[TBL] [Abstract][Full Text] [Related]
39. Which inhibitor of the renin-angiotensin system should be used in chronic heart failure and acute myocardial infarction?
McMurray JJ; Pfeffer MA; Swedberg K; Dzau VJ
Circulation; 2004 Nov; 110(20):3281-8. PubMed ID: 15545527
[No Abstract] [Full Text] [Related]
40. Pharmacotherapy Treatment Patterns, Outcomes, and Health Resource Utilization Among Patients with Heart Failure with Reduced Ejection Fraction at a U.S. Academic Medical Center.
Bress AP; King JB; Brixner D; Kielhorn A; Patel HK; Maya J; Lee VC; Biskupiak J; Munger M
Pharmacotherapy; 2016 Feb; 36(2):174-86. PubMed ID: 26841333
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
